Skip to search formSkip to main contentSkip to account menu

Raf Kinase Inhibitor HM95573

Known as: HM95573 
An orally available inhibitor of members of the Raf family of serine/threonine protein kinases, with potential antineoplastic activity. Upon… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.
2570Background: HM95573 is a novel and selective RAF kinase inhibitor which showed potent anti-tumor activities in BRAF, KRAS and… 
2016
2016
A selective and potent pan-RAF inhibitor, HM95573 exhibits high therapeutic potential as a next-generation RAF inhibitor by direct inhibition of RAF kinase activity in BRAF or RAS mutant cancers
2015
2015
Abstract 2607: Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies
The mitogen-activated protein kinase (MAPK) pathway is particularly important for the survival and proliferation of tumor cells… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)